Media headlines about ArQule (NASDAQ:ARQL) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ArQule earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.3925043204904 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

ArQule (ARQL) traded up 0.5631% during midday trading on Monday, reaching $1.0358. The company had a trading volume of 39,393 shares. ArQule has a 12-month low of $0.92 and a 12-month high of $1.82. The stock’s 50 day moving average is $1.21 and its 200 day moving average is $1.19. The firm’s market capitalization is $73.69 million.

ArQule (NASDAQ:ARQL) last released its quarterly earnings data on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. ArQule had a negative return on equity of 135.68% and a negative net margin of 482.44%. During the same quarter last year, the business posted ($0.07) EPS. Equities research analysts expect that ArQule will post ($0.43) earnings per share for the current year.

Separately, Zacks Investment Research raised ArQule from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Thursday.

COPYRIGHT VIOLATION NOTICE: “ArQule (ARQL) Given News Sentiment Rating of 0.22” was reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/14/arqule-arql-given-news-sentiment-rating-of-0-22.html.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Insider Buying and Selling by Quarter for ArQule (NASDAQ:ARQL)

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.